Durect corporation says do not plan to continue development of topical dur-928 in psoriasis

Durect corporation announces top-line results from phase 2a clinical trial in patients with psoriasis.durect - dur-928 did not demonstrate benefit over vehicle (placebo) based on investigator's global assessment.durect - daily topical application of dur-928 was well tolerated with no meaningful differences in adverse events between treatment & placebo groups.durect - based on top-line data, do not plan to continue development of topical dur-928 in psoriasis.
DRRX Ratings Summary
DRRX Quant Ranking